Menu
← Oncology Approval Tracker
FDA DECISION ·
Crysvita
burosumab-twza · Kyowa Kirin
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children ages two and older with FGF23-related hypophosphatemia from tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that could not be located or curatively resected.
LAMPGEN ANALYSIS
Why it matters
Addressed the phosphate-wasting complication of a tumor when definitive tumor removal was unavailable.
What research teams should watch
Coordinate tumor localization and phosphate testing with metabolic bone specialists.
PRIMARY RECORDS